The objective of this study is to evaluate the safety and efficacy of a 0.1% formulation of
rapamune cream in children with Tuberous Sclerosis Complex (TSC), ages 3 years and older, who
have facial angiofibromas that would benefit from treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Le Bonheur Children's Hospital
Collaborators:
Pfizer University of Tennessee Health Science Center